Genomic Sequencing in Pediatric Cancer: For Every Patient at Every Relapse
More than one-third of tumors sequenced carried a high mutation burden.
Endocrine Cancer Mobile
ENDOCRINE CANCER ADVISOR
Endocrine Cancer News
Nomogram Could Aid Clinical Decision-Making for Gastroenteropancreatic Neuroendocrine Tumors
The nomogram proved more accurate than TNM staging for predicting 3-year and 5-year overall survival.
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
‘Practice-Changing’ Results With Sunitinib in Malignant Pheochromocytoma and Paraganglioma
The 12-month progression-free survival rate was 35.9% with sunitinib and 18.9% with placebo.
Cabometyx Approved for Radioactive Iodine-Refractory Differentiated Thyroid Cancer
The approval was based on data from the phase 3 COSMIC-311 study.
Multifocality Appears to Increase Risk of Recurrence in Papillary Thyroid Carcinoma
The risk of recurrence varied by patient age, tumor size, and number of foci.
Vorinostat Plus MIBG Proves More Effective Than Other MIBG Regimens in Relapsed or Refractory Neuroblastoma
Response rates were highest with MIBG plus vorinostat.
‘Excellent’ Outcomes and Room for Improvement in Pediatric Adrenocortical Carcinoma
Patients with stage II or IV disease did not fare as well as patients with stage I or III disease.
Study Reveals Less Toxic Induction Regimen for High-Risk Neuroblastoma
The rCOJEC regimen was less toxic than the MSKCC-N5 regimen.
Response Endpoints Deemed ‘Poor Surrogates’ for Overall Survival in Trials of Immune Checkpoint Inhibitors
Response endpoints were not strongly correlated with overall survival at the trial level.
Vandetanib and Cabozantinib Deemed Effective in Real-World Study of Medullary Thyroid Cancer
The overall survival rate at 1 year was 86% with vandetanib and 70% with cabozantinib.
Local Resection Is ‘Sufficient’ for Parathyroid Carcinoma
Patients with parathyroid carcinoma after localized resection for a presumed benign indication should undergo close monitoring for recurrence rather than radical surgery.
Platinum Chemotherapy Appears to Cause Clonal Expansion Leading to Myeloid Neoplasms in Children With Neuroblastoma
Children treated for neuroblastoma developed myeloid neoplasms with specific platinum chemotherapy-associated mutation signatures.
Lenvatinib Produces ‘Strong’ Responses in Resistant Gastroenteropancreatic Neuroendocrine Tumors
The response rate was higher for patients with pancreatic NETs than for those with gastrointestinal NETs.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Lenvatinib Monotherapy Produces Low Response Rate in Anaplastic Thyroid Cancer
In a phase 2 trial, lenvatinib produced an objective response rate of about 3%.
Closing the Gap Between Cancer Patients and Researchers: A Patient Advocate’s Perspective on GRASP
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
The Past, Present, and Future of GRASP: Connecting Cancer Researchers, Clinicians, and Patient Advocates
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Cabozantinib Improved PFS, May Be New Standard for Radioiodine-Refractory Thyroid Cancer
Cabozantinib significantly improved progression-free survival, and there was a trend toward improved overall survival.
Mutational Risk Not Associated With Distant Metastasis in Medullary Thyroid Cancer
Researchers identified risk factors for distant metastasis in sporadic and hereditary medullary thyroid cancer.
Extended Induction Chemotherapy Does Not Improve Survival in High-Risk Neuroblastoma
Researchers found that the therapy did not improve EFS or OS in high-risk patients and also led to an increase in toxic side effects.
Cabozantinib Gets Breakthrough Tx Status for Differentiated Thyroid Cancer
The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
Exposure to Light at Night May Increase Risk for Thyroid Cancer
Investigators tested the hypothesis that greater exposure to light at night (LAN) is associated with an increased risk for thyroid cancer by studying artificial outdoor LAN measured by satellite imagery in relation to thyroid cancer.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...